Sofinnova's STENTYS IPO raises €22.7m

Sofinnova has bought additional shares, but its overall stake in the company has decreased because of the number of shares in the issue. The company, listed on NYSE Euronext Paris and was twice oversubscribed at the offering price of €12 per share. Capital raised through the IPO will support development and commercialisation of the company's medical devices.

Sofinnova was the sole institutional investor in the company's series-A funding round. The amount raised from the IPO is subject to the exercise of an over-allotment option.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Exits
• France
• Sofinnova